Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 7:27 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 4,019 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Part 3 Clear all

Conditions: Substance Use Disorders
Interventions: SBIRT, SBIRT+RMC-PC; Behavioral
Lead sponsor: Chestnut Health Systems; Other
Eligibility: 18 Years and older
Enrollment: 266 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 4
States / cities: Chicago, Illinois • Lansing, Illinois • Oak Park, Illinois

Conditions: Inpatient Experience Survey Administration, Inpatient Experience Survey Response, Inpatient Pediatric Care, Inpatient Pediatric Engagement and Shared Decision-Making
Interventions: Text-Only Enrollment Strategy, Text Plus In-Person Enrollment Strategy, Anonymous Safety Reporting with Impact Website, Identified Safety Reporting, Safety Reporting Integration Toolkit; Behavioral · Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 13 Years and older
Enrollment: 21,800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 8
States / cities: Los Angeles, California • Oakland, California • Sacramento, California + 5 more

Conditions: Solid Tumor, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer
Interventions: DS-3939a, Pembrolizumab, Carboplatin, Pemetrexed, DS-1103a; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 7
States / cities: Fayetteville, Arkansas • Los Angeles, California • Tampa, Florida + 4 more

Conditions: Assaultive Behavior, Violence, Sexual Assault and Rape, Helping Behavior
Interventions: SCREAM Theater Dose 1, SCREAM Theater Doses 2 & SCREAM Theater Dose 3, SCREAM Theater Dose 4; Behavioral
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years to 21 Years
Enrollment: 4,385 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: New Brunswick, New Jersey

Conditions: Skin Cancer
Interventions: Nevisense 3.0, Dermlite Cam, Skin biopsy, Barco Demetra; Device · Procedure
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 90 Years
Enrollment: 149 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: New York, New York

Conditions: Healthy Volunteers, Pulmonary Arterial Hypertension
Interventions: LTP, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 232 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 19
States / cities: Scottsdale, Arizona • Orange, California • Stanford, California + 16 more

Conditions: Infection, Human Immunodeficiency Virus, HIV Infections
Interventions: GSK2838232, Cobicistat; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 12
States / cities: Birmingham, Alabama • Bakersfield, California • Los Angeles, California + 8 more

Conditions: Metastatic Castration-resistant Prostate Cancer and Other Solid Tumors
Interventions: NOX66, EBRT; Drug · Radiation
Lead sponsor: Noxopharm Limited; Industry
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 2
States / cities: Beverly Hills, California • Houston, Texas

Conditions: OBESITY, HYPERTENSION, PURE AUTONOMIC FAILURE, SHY-DRAGER SYNDROME
Interventions: Trimethaphan, Pseudoephedrine; Drug
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 128 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2017
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Ankle Fractures
Interventions: Ankle Muscle Power (AMP) program, Standard of Care; Other · Behavioral
Lead sponsor: Brian W. Noehren; Other
Eligibility: 18 Years to 50 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Neurofibromatosis 1, Plexiform Neurofibroma
Interventions: Selumetinib; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 1 Year to 8 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 15
States / cities: Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 11 more

Conditions: CoronaVirus Disease-2019 (COVID-19)
Interventions: ABBV-47D11, Placebo for ABBV-47D11, ABBV-2B04, Placebo for ABBV-2B04; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 11
States / cities: Glendale, California • Cutler Bay, Florida • Miami, Florida + 8 more

Conditions: Opioid-use Disorder
Interventions: Recovery Management Checkups (RMC), RMC-Adaptive; Combination Product
Lead sponsor: Chestnut Health Systems; Other
Eligibility: 18 Years and older
Enrollment: 455 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Macular Degeneration
Interventions: Zifibancimig, Ranibizumab, Port Delivery Platform; Drug · Device
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 50 Years and older
Enrollment: 177 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 36
States / cities: Mesa, Arizona • Phoenix, Arizona • Encino, California + 32 more

Conditions: Healthy
Interventions: Simeprevir 75 mg, Odalasvir 25 mg, Odalasvir 12.5 mg, Odalasvir 75 mg, AL-335 800 mg, Lansoprazole 30 mg, Omeprazole 20 mg; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Rheumatoid Arthritis
Interventions: PDA001, Vehicle Controlled Placebo; Biological · Drug
Lead sponsor: Celularity Incorporated; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 16
States / cities: Anniston, Alabama • Arcadia, California • Los Angeles, California + 12 more

Conditions: Cancer
Interventions: Custirsen, paclitaxel and carboplatin; Drug
Lead sponsor: Achieve Life Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 4
States / cities: Detroit, Michigan • Dallas, Texas • San Antonio, Texas + 1 more

Conditions: Cancer - Solid Tumors and B-Cell Non-Hodgkin's Lymphoma
Interventions: Urelumab (BMS-663513); Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 12
States / cities: Los Angeles, California • Stanford, California • Chicago, Illinois + 9 more

Conditions: Colorectal Cancer, Colorectal Adenocarcinoma, Colorectal Cancer Metastatic, Advanced Colorectal Carcinoma, Advanced Colorectal Adenocarcinoma
Interventions: VS-6766/avutometinib, Cetuximab, Pill Diary; Drug · Other
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Alpha1-Antitrypsin Deficiency
Interventions: Fazirsiran Injection; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2033
U.S. locations: 5
States / cities: La Jolla, California • Redwood City, California • Gainesville, Florida + 2 more

Conditions: HIV Infections
Interventions: VH3810109, rHuPH20; Biological
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Neoplasms, Tumor
Interventions: IMC-TR1; Biological
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 3
States / cities: Nashville, Tennessee • Houston, Texas • San Antonio, Texas

Conditions: Trauma Injury
Interventions: Cryoprecipitate, Red Blood Cells, Plasma, Platelets, Whole Blood; Biological
Lead sponsor: Bryan Cotton; Other
Eligibility: 16 Years and older
Enrollment: 1,604 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Body Weight Changes
Interventions: MicroDiet, Healthy Diet; Behavioral
Lead sponsor: Pennington Biomedical Research Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Search by objective public record fields.

Recovery Management Checkups for Primary Care Experiment

FIQS Dissemination and Implementation

A Study of DS-3939a in Participants With Solid Tumors

Experimentally Testing the Effectiveness of a Campus-based Bystander Intervention

SpotCheck: Comparison of Enhanced Telemedicine Versus In-person Evaluation for the Diagnosis of Skin Cancer

A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)

Safety and Efficacy Study of GSK2838232 in Human Immunodeficiency Virus (HIV)-1 Infected Adults

A Study of NOX66 and External Beam Radiotherapy in Patients With Metastatic Castration-resistant Prostate Cancer and Other Solid Tumors

The Autonomic Nervous System and Obesity

Efficacy and Clinical Feasibility of the Ankle Muscle Power (AMP) Program for Return to Duty After an Ankle Fracture

Selumetinib for the Prevention of Plexiform Neurofibroma Growth in NF Type 1

Study to Assess Adverse Events and How Intravenous (IV) ABBV-47D11 and IV ABBV-2B04 Given Alone and in Combination Moves Through the Body of Adult Participants With Coronavirus Disease 2019 (COVID-19)

Recovery Management Checkups for Opioid Use Disorder Experiment

Study of Zifibancimig in Participants With Neovascular Age-related Macular Degeneration

Study to Assess the Relative Bioavailability of Fixed-Dose Combination (FDC) Tablet (Simeprevir, Odalasvir and AL-335) Compared With Single Agents Administered Together, and to Assess the Effect of Multiple-Dose Lansoprazole or Omeprazole on Single-Dose Pharmacokinetics of SMV, ODV, and AL-335 (FDC)

Study of Human Placenta-derived Cells (PDA001) to Evaluate the Safety and Effectiveness for Patients With Active Rheumatoid Arthritis

A Clinical Study in Cancer Patients to Investigate the Potential Impact of Custirsen, on the Blood Levels of the Chemotherapeutic Drug, Paclitaxel, When Given Together as Part of a Treatment Regimen

Safety, Tolerability, Pharmacokinetics, and Immunoregulatory Study of Urelumab (BMS-663513) in Subjects With Advanced and/or Metastatic Solid Tumors and Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

A Study of VS-6766 and Cetuximab in Patients With Advanced Colorectal Cancer

An Extension Study to Learn About the Long-Term Safety of Fazirsiran and if Fazirsiran Can Help People With Alpha-1 Antitrypsin Liver Disease

A Study to Investigate the Safety and Pharmacokinetics of a Single Dose of VH3810109 (Also Known as GSK3810109), Administered Either Subcutaneously (SC) With rHuPH20 or Intravenously (IV), in Healthy Adult Participants

A Study of IMC-TR1 in Participants With Advanced Solid Tumors

Early Use of Cryoprecipitate With Major Hemorrhage Protocol (MHP) Activation

The Effects of Formula Diet on Body Weight, Body Composition, and Biomarkers for Disease Compared to a Standard Diet